Updates are available Correction dated 2022-11-29
Click to view Correction: https://doi.org/10.1038/s41386-022-01504-0
-
Authors
Saarinen, Marcus
Mantas, Ioannis
Flais, Ivana
Ågren, Richard
Sahlholm, Kristoffer
Millan, Mark J.
Svenningsson, Per
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2019-01422, 2019-01422)
- License Information
-
More Information
Article History
Received: 6 March 2022
Revised: 4 July 2022
Accepted: 30 July 2022
First Online: 13 September 2022
Change Date: 29 November 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41386-022-01504-0
Competing interests
: MJM is a consultant for PsychoGenics who were involved in the initial discovery and experimental characterization of SEP-856. At that time, he was not involved with the Company. He has no other interests to declare. All other authors do not have anything to disclose. This study was supported by grants from Karolinska Institutet (to MS, PS), Vetenskapsrådet (to PS, MS, IM, IF, number 2019-01422), Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, John and Lucille van Geest Foundation (to PS) Åhlénstiftelsen (to KS, number mB3 h18), Stiftelsen Lars Hiertas Minne (to KS and RÅ grant numbers FO2013-0609 and FO2020-0289), and Magnus Bergvalls stiftelse (to KS and RÅ, grant numbers 2018-02980 and 2020-04055). KS is currently a fellow at the Wallenberg Center for Molecular Medicine at Umeå University. PS and RÅ are funded by Region Stockholm.
